Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Adherence to antidepressant therapy: clinical experience on the example of agomelatine

https://doi.org/10.14412/2074-2711-2022-4-82-86

Abstract

The review article provides data on the prevalence and treatment problems of depression, highlights the issues of adherence to antidepressant therapy, investigation of the safety and efficacy of agomelatine in real clinical settings. The results of a prospective observational multicenter cohort study of agomelatine in clinical practice are analyzed in detail, taking into account the effect of treatment on the social functioning of patients. The results obtained in a sample representative for depression, including patients with comorbidities, confirm the long-term efficacy and good tolerability of agomelatine in daily practice, which is the basis for adherence to therapy and achievement of the goal of depression treatment

About the Author

N. N. Petrova
St. Petersburg State University
Russian Federation

199034, Saint Petersburg, Universitetskaya Embankment, 7–9


Competing Interests:

The conflict of interest has not affected the results of the investigation.



References

1. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3 IGO.

2. Chekroud AM, Foster D, Zheutlin AB, et al. Predicting Barriers to Treatment for Depression in a U.S. National Sample: A Cross-Sectional, Proof-of-Concept Study. Psychiatr Serv. 2018 Aug 1;69(8):927-34. doi:10.1176/appi.ps.201800094. Epub 2018 Jul 2.

3. Thornicroft G, Chatterji S, Evans-Lacko S, et al. Undertreatment of people with major depressive disorder in 21 countries. Br J Psychiatry. 2017 Feb;210(2):119-24. doi:10.1192/bjp.bp.116.188078. Epub 2016 Dec 1.

4. Pompili M, Venturini P, Palermo M, et al. Mood disorders medications: predictors of nonadherence:review of the current literature. Expert Rev Neurother. 2013 Jul;13(7):809-25. doi:10.1586/14737175.2013.811976

5. Keyloun KR, Hansen RN, Hepp Z, et al. Adherence and persistence across antidepressant therapeutic classes: a retrospective claims analysis among insured us patients with Major Depressive Disorder (MDD). CNS Drugs. 2017 May;31(5):421-32. doi:10.1007/s40263-017-0417-0

6. Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry. 2009 Jun 16;9:38. doi:10.1186/1471-244X-9-38

7. Semahegn A, Torpey K, Manu A, et al. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020 Jan 16;9(1):17. doi:10.1186/s13643-020-1274-3

8. Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012 May;9(5-6):41-6.

9. Rossom RC, Shortreed S, Coleman KJ, et al. Antidepressant adherence across diverse populations and health care settings. Depress Anxiety. 2016 Aug;33(8):765-74. doi:10.1002/da.22532. Epub 2016 Jun 20.

10. Van der Voort TY, Seldenrijk A, van Meijel B, et al. Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. J Clin Psychiatry. 2015 Jun;76(6):e809-14. doi:10.4088/JCP.14m09548

11. Ishak WW, Mirocha J, James D, et al. Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up. Acta Psychiatr Scand. 2015 Jan;131(1):51-60. doi:10.1111/acps.12301. Epub 2014 Jun 23.

12. Rush AJ, Thase ME. Improving depression outcome by patient-centered medical management. Am J Psychiatry. 2018 Dec 1;175(12):1187-98. doi:10.1176/appi.ajp.2018.18040398. Epub 2018 Sep 17.

13. Ho SC, Jacob SA, Tangiisuran B. Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: a qualitative study. PLoS One. 2017 Jun 14;12(6):e0179290. doi:10.1371/journal.pone.0179290

14. Petrova NN, Kucher EO. Treatment side effects and compliance in patients with depression. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2012;112(11):77-85 (In Russ.)

15. Andrade LH, Alonso J, Mneimneh Z, et al. Barriers to mental health treatment: results from the WHO World Mental Health surveys. Psychol Med. 2014 Apr;44(6):1303-17. doi:10.1017/S0033291713001943. Epub 2013 Aug 9.

16. Brenes GA, Danhauer SC, Lyles MF, et al. Barriers to mental health treatment in rural older adults. Am J Geriatr Psychiatry. 2015 Nov;23(11):1172-8. doi:10.1016/j.jagp.2015.06.002. Epub 2015 Jun 17.

17. Gerlach LB, Chiang C, Kales HC. The start predicts the finish: factors associated with antidepressant nonadherence among older veterans during the acute and maintenance treatment phases. J Clin Psychiatry. 2019 Mar 26;80(3):18m12476. doi:10.4088/JCP.18m12476

18. Burton C, Cochran AJ, Cameron IM. Restarting antidepressant treatment following early discontinuation – a primary care database study. Fam Pract. 2015 Oct;32(5):520-4. doi:10.1093/fampra/cmv063. Epub 2015 Aug 5.

19. Sirey JA, Banerjee S, Marino P, et al. Adherence to Depression Treatment in Primary Care: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Nov 1;74(11):1129-35. doi:10.1001/jamapsychiatry.2017.3047

20. Gorwood P, Benichou J, Moore N, et al. Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France. Clin Drug Investig. 2020 Nov;40(11):1009-20. doi:10.1007/s40261-020-00957-9

21. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network metaanalysis. Lancet. 2018 Apr 7;391(10128):1357-66. doi:10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.

22. Vieta E, Loft H, Florea I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. Eur Neuropsychopharmacol. 2017 Sep;27(9):877-84. doi:10.1016/j.euroneuro.2017.06.012. Epub 2017 Jul 8.

23. Laux G; VIVALDI Study Group. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry. 2012 Nov;45(7):284-91. doi:10.1055/s-0032-1309003. Epub 2012 May 16.

24. Udristoiu T, Dehelean P, Nuss P, et al. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25–50 mg/day) and escitalopram (10–20 mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study. J Affect Disord. 2016 Jul 15;199:6-12. doi:10.1016/j.jad.2016.03.048. Epub 2016 Mar 26.

25. Montejo AL, Deakin JF, Gaillard R, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale. J Psychopharmacol. 2015 Oct;29(10):1119-28. doi:10.1177/0269881115599385. Epub 2015 Aug 12.

26. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009 Jun;29(3):259-66. doi:10.1097/JCP.0b013e3181a5233f

27. Perlemuter G, Cacoub P, Valla D, et al. Characterisation of agomelatine-induced increase in liver enzymes: frequency and risk factors determined from a pooled analysis of 7605 treated patients. CNS Drugs. 2016 Sep;30(9):877-88. doi:10.1007/s40263-016-0351-6

28. Billioti de Gage S, Collin C, Le-Tri T, et al. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database. CNS Drugs. 2018 Jul;32(7):673-84. doi:10.1007/s40263-018-0537-1


Review

Views: 198


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)